This modification served as the activating component for click-release of PROTAC prodrugs, enabling targeted degradation of BRD4 and B-Cell Lymphoma-XL (BCL-XL) proteins in cancer cells while sparing noncancerous normal cells. The gene discussed is BRD4; the disease is cancer.